Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
230
resultados
Última actualización
11/03/2026 [07:04:00]
Resultados 75 a 100 de 230
Resumen de: WO2026049650A1
The invention relates to the fields of colloidal chemistry and medicinal chemistry. A surfactant containing branched hydrophobic chains with amino acid residues at the branching point is characterized by general formula (I), where R1-A-R2 represents an amino acid residue; k can be equal to 1, 2 or 3; l can be equal to 3, 4, 5, 6 or 7; the amino acid residue has an L configuration; R1 and R2 are the same or different residues from the list shown; m is an integer from 4 to 13. New compounds are obtained which provide for better binding of molecules inside lipid nanoparticles (LNPs), as well as more uniform packing of molecules inside LNPs, without the formation of ordered phases such as a lamellar phase.
Resumen de: WO2026049467A1
The present invention relates to a composition for alleviating or treating hair loss in which a hair loss drug is loaded in lipid nanoparticles. The lipid nanoparticles contain 0.30 mol% or more of a hydrophobic drug such as finasteride or dutasteride relative to the lipid nanoparticles and are loaded with the hydrophobic drug at an encapsulation rate of 90.0% or more, and thus have the advantage of being able to maintain water dispersibility for a long period of time while increasing transdermal delivery. Therefore, the present invention can more effectively alleviate symptoms of male pattern hair loss on the scalp where localized hair loss or thinning of hair occurs.
Resumen de: WO2026048880A1
The present invention provides a nanoparticle with which it is possible, safely, efficiently, and stably over a long period of time, to introduce siRNA used for RNA interference into an intervertebral disk cell. This nanoparticle is used for prevention or treatment of intervertebral disk degeneration, and has a biodegradable hydrogel and a ribonucleic acid molecule that is retained by a particle of the biodegradable hydrogel and that selectively inhibits an activity of a mammalian target of rapamycin (mTOR) complex.
Resumen de: WO2026047519A1
Described herein are pharmaceutical compositions and methods of their use for the treatment of cancer. The pharmaceutical compositions comprise a first anticancer drug formulated as nanoparticles or microparticles, the nanoparticles or microparticles uniformly dispersed in the injectable hydrogel polymer matrix formulation. This matrix comprises an anionic polymer and an inverse thermal gelling polymer, which transitions from a liquid to a gel state at specific temperatures and demonstrates shear-thinning properties to facilitate injection and gel reformation. The pharmaceutical compositions are administered intratumorally into solid tumors to treat cancer in a subject requiring such treatment. The method may additionally include systemic administration of a therapeutically effective amount of a second anticancer drug.
Resumen de: WO2026046237A1
Provided is a lung-targeting lipid compound, specifically relating to a compound as shown in formula (I), or an isotopic variant, tautomer or stereoisomer thereof, or a pharmaceutically acceptable salt thereof. Also provided are a nanoparticle pharmaceutical composition comprising the compound, and a use of the compound and the composition thereof in lung targeted delivery of nucleic acids.
Resumen de: AU2026200991A1
Aspects of the present disclosure provide for improved mycobacterium tuberculosis vaccine compositions of ionizable lipid nanoparticles for the delivery of immunogenic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in dendritic cells. In some embodiments, the incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-dioxolane or heterocyclic ketal ionizable lipids in the formulation provided high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Other aspects of the present disclosure provide mRNA that encodes for concatenated peptides encoding for multiple MHC-II tuberculosis epitopes, and optionally includes a second mRNA encoding for concatenated MHC-I tuberculosis epitopes. eb e b
Resumen de: WO2026045510A1
Provided are a metal-organic framework nanomaterial, a preparation method therefor, and a use thereof, belonging to the technical field of bionanomaterials, and resolving the technical problem of inhibiting atherosclerosis using biomimetic metal-organic framework nanoenzymes. The solution is: the components of the of the metal-organic framework nanomaterial and the ratio thereof are: metal ions Ce4+ and a ligand fumaric acid in a molar ratio of 1:5. The preparation method therefor is: measuring an FA regulator and water to prepare a mixed solution, then adding fumaric acid and cerium ammonium nitrate dropwise into the mixed solution, stirring at room temperature, centrifuging, repeatedly washing alternately with water and ethanol, and finally drying overnight in a vacuum oven. A simple, efficient and convenient method for synthesizing the metal-organic framework nanomaterial is provided. The synthesized metal-organic framework nanomaterial has excellent CEH-like enzyme activity and intrinsic antioxidant activity, and can be used to increase lipid efflux and reduce lipid uptake, and decrease ox-LDL-induced foam cell formation, thereby alleviating atherosclerosis.
Resumen de: WO2026050351A1
LNPs can penetrate uterine mucosa to deliver therapeutic or prophylactic agents such as functional nucleic acids to the endometrium. Targeting of the LNPs using ligands expressed at particular times in an endometrial cycle ensures that the LNPs penetrate and release the mRNA primarily to the tissue associated with the peak time period for implantation, thereby providing a means to address infertility, as well as for treatment of other disorders such as cancer.
Resumen de: WO2026046962A1
The present disclosure provides pharmaceutical compositions comprising nanoparticles, wherein the nanoparticles each comprise a micelle comprising an amphiphilic polymer, and at least one peptide. The present disclosure further provides methods of treating an autoimmune disease (e.g., multiple sclerosis, type 1 diabetes) in a human subject in need thereof comprising administering the pharmaceutical compositions provided herein.
Resumen de: WO2026047192A1
The present invention generally relates to the field of ionizable (also termed cationic) lipids, and in particular provides a novel type of such lipids as represented by formula (I). The present invention further provides methods for making such lipids as well as uses thereof, in particular in the preparation of nanoparticle compositions, more in particular nanoparticle compositions comprising nucleic acids. It further provides vaccine formulations comprising nanoparticle compositions based on the ionizable lipid disclosed herein.
Resumen de: WO2026047418A1
Extracellular vesicles (PDEVs) for reaching the blood-brain barrier characterized by: be obtained from oranges from organic farming and to contain within the lipid membrane a ratio between the concentration of Phosphatidylethanolamine (PE) and the concentration of Phosphatidic Acid (PA) between 8 and 15.
Resumen de: US20260062715A1
Disclosed is a method for the enhancement of the transduction of a target cells by a viral vector using a cationic block-copolymer introduced as an additive alone or formulated with nanoparticles. The method includes a step of contacting a target cells with viruses and a cationic block co-polymer. The structure of this additive incorporates both hydrophilic and hydrophobic regions which represents different areas in the backbone of the polymer. This polymeric construction is ended by cationic chemical functions which contribute to further enhance the viral transduction. Also disclosed are new cationic poloxamers that can be used in the disclosed method. Furthermore, another embodiment is the colloidal stabilization of iron-based nanoparticles using these polymers and their use in increasing transduction efficiency.
Resumen de: US20260060221A1
The present invention relates to a method for producing a nonhuman primate animal model of cerebral infarction, comprising administering endothelin to basal ganglia and thalamic region of a nonhuman primate, and thereby inducing basal ganglia damage, thalamus damage, and internal capsule damage; and a pharmaceutical composition for the treatment of cerebral infarction at a subacute to chronic stage, penetrating branch infarction, or cerebral infarction having brain damage in a penetrating branch territory, comprising a NeuroD1 protein or a polynucleotide encoding the NeuroD1 protein.
Resumen de: US20260062688A1
A drug for genetic modification according to an embodiment is a drug for performing genome editing on a gene in a hematopoietic stem cell. The drug for genetic modification contains a genome editing molecule and a lipid nanoparticle encapsulating the genome editing molecule. The lipid nanoparticle includes a lipid membrane having a lumen. The lipid composition contains at least a first lipid (FFT-10) and a second lipid (FFT-20) in the lipid composition. The amount of the second lipid is larger than that of the first lipid, the total amount of the first lipid and the second lipid is 40 mol % or less, and the total amount of the cationic lipid is 60 mol % or less.
Resumen de: AU2026200990A1
The present disclosure provides for improved compositions of ionizable lipid nanoparticles for the delivery of therapeutic nucleic acids to cells. Anionic phospholipids, including phosphatidyl serine and phosphatidylglycerol are included in the lipid nanoparticles to increase the transfection efficiency in human dendritic cells. The further incorporation of mono-unsaturated alkyl chain analogs in dimethylaminopropyl-di oxolane or heterocyclic ketal ionizable lipids in the formulation demonstrated high levels of transfection in human dendritic cells, compared to other ionizable lipids in the same family, and demonstrated good stability to oxidative damage. Finally, the use of an ammonium salt of phosphatidylserine allows for the efficient production of PS-targeted LNPs. 20 eb e b
Resumen de: US20260062486A1
Certain embodiments of the invention provide a method for treating a Hepatitis B virus infection and/or ameliorating one or more symptoms associated with a Hepatitis B virus infection in a mammal, the method comprising the step of administering to the mammal a therapeutically effective amount of an anti-PD-1 antibody, or fragment thereof.
Resumen de: US20260061018A1
A method for treating a gastrointestinal condition includes preparing an aqueous extract of bioactive compound by adding dried green tea material to hot water and filtering the aqueous extract; adding a solution of an iron-containing compound to the filtered aqueous extract to form a complex or chelate of the bioactive compounds with iron; and drying the solution at a temperature between 80 to 150 degrees Fahrenheit to obtain a fine granular or powdered state.
Resumen de: WO2024223624A1
The invention concerns a new galenic formulation of CFT (clofoctol) allowing the administration of this antibiotic in aerosol form with the objective of treating pulmonary infections (COVID-19, influenza), cancer and inflammation thus targeting the diseased tissue while avoiding the problems of solubility of CFT and toxicity associated with this drug. This new formulation allows to answer these problems and concerns the development of polymeric nanoparticles (Nanoparticles) in suspension in an aqueous phase intended to be administrated in a form of aerosol or spray, said Nanoparticles comprising PLGA and PLGA-PEG polymers, allowing to obtain an effective encapsulation of CFT and a controlled release of CFT at the pulmonary level.
Resumen de: WO2024245589A1
The invention relates to a composition comprising a cold-water insoluble crosslinked dextrin and a fatty acid having 8 to 17 carbon atoms. This invention also relates to a method for making such composition. The invention also relates to the use of a combination of a cold-water insoluble crosslinked dextrin and of a fatty acid having 8 to 17 carbon atoms for increasing the epithelial permeation of an active ingredient, or for the epithelial delivery of an active ingredient.
Resumen de: US20260053933A1
The present invention provides nuclease-resistant nucleic acid nanostructures, pharmaceutical compositions thereof, pharmaceutical and diagnostic uses thereof as well as a method of producing nucleic acid nanostructures.
Resumen de: US20260048012A1
The present invention concerns a method for the production, purification, and stabilization of plant-derived nanovesicles (PDVs). It also concerns a pharmaceutical composition comprising the PDVs obtained by this method for hypocholesterolemic, hypoglycemic, hypolipidemic, anti-ageing, and antioxidant use.
Resumen de: CA3205091A1
Novel chimeric peptides comprise an N-cadherin binding domain for binding N-cadherin, which is expressed on the surface of cells, in particular smooth muscle cells, and a fibronectin-binding domain, which binds surrounding extracellular matrix and a binding site for fibronectin. The chimeric peptides can be loaded on to nanoparticles, suitably degradable polar hydrophobic ionic polyurethane (D-PHI) nanoparticles for delivery, which can be incorporated into coatings for medical devices, including stents and balloons.
Resumen de: GB2643844A
Provided herein are gene editing systems and compositions directed to effectuate in vivo edits in the LPA gene. Treatment or prevention of cardiovascular disease through disruption of the production of apo(a) through genetic editing and the reduction of the blood lipoprotein(a) Lp(a) concentration is disclosed herein. Disclosed are nickase-based gene editing systems designed to effectuate the installation of insertions and/or deletions (indel variants) and/or non-synonymous variants in the coding sequence of LPA. The nickase-based gene editing systems generally comprise one or more mRNAs that encode one or more nickases and a plurality of guide oligonucleotides (e.g., gRNAs) and may be delivered in vivo to a mammalian subject in need thereof via a suitable delivery system, such as lipid nanoparticles (LNPs) (with or without GalNAc targeting moieties) intravenously, or otherwise, administered to a patient as potentially a once-and-done therapeutic. The manufacturing, use, and formulation of the gene editing systems and compositions are also disclosed.
Resumen de: WO2024165949A1
The present invention relates to a method for the production of gold nanoparticles (AuNPs) coated with glutathione and Li+ ions, hereinafter designated as LiG-AuNPs, to a method for the preparation of aggregates of said nanoparticles and to the use of said nanoparticles, aggregates or compositions thereof which comprise them for therapeutic use. LiG-AuNPs then are an effective instrument in inhibiting GSK-3 and its downstream molecular targets, while keeping the lithium extracellular concentration levels below the systemic toxicity threshold (1.5 mEq/L), and exerting an antioxidant action by means of the glutathione present on their surface.
Nº publicación: JP2026035723A 04/03/2026
Solicitante:
ゾエティス・サービシーズ・ユーケー・リミテッド
Resumen de: US2025297026A1
The invention relates to antibodies and antigen binding portions thereof that binds canine CD20. The present invention also relates to compositions and methods for the treatment of a condition mediated by B-cells in a canine subject.
BOPI
Sede Electrónica
